Revenue was almost entirely a R&D tax refund and interest on cash. But what what more can we expect?
A lot of the R&D investment has been made so current cash levels should last the next 2-3 years as new revenue starts trickling through the door.
People have to realise that this business is going through a monumental shift in direction. In the space of a few years it will go from being a one product business to a multi product, generic business.
We will have a couple of years before we start generating any decent revenue. But I am confident that earnings will be back what they were a couple of years ago if not higher - but across multiple products.
Further to this, there is very little that the company can tell the market. Impatient shareholders and don't understand the fundamentals of the shift in strategy will sell (if they haven't already sold).
This investment opportunity will favour the patient and brave and will be a multi bagger over the next 3-5 years.
ACR Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)